Audeo Oncology (Audeo Oncology) Return-on-Tangible-Equity : -451.73% (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Audeo Oncology's annualized net income for the quarter that ended in Sep. 2012 was $-20.54 Mil. Audeo Oncology's average shareholder tangible equity for the quarter that ended in Sep. 2012 was $4.55 Mil. Therefore, Audeo Oncology's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2012 was -451.73%.

The historical rank and industry rank for Audeo Oncology's Return-on-Tangible-Equity or its related term are showing as below:

AURX's Return-on-Tangible-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 6.475
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Audeo Oncology Return-on-Tangible-Equity Historical Data

The historical data trend for Audeo Oncology's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Return-on-Tangible-Equity Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Return-on-Tangible-Equity

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Return-on-Tangible-Equity	-	-	-	-451.73

Competitive Comparison of Audeo Oncology's Return-on-Tangible-Equity

For the Drug Manufacturers - General subindustry, Audeo Oncology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Return-on-Tangible-Equity falls into.

Audeo Oncology Return-on-Tangible-Equity Calculation

Audeo Oncology's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2012 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(A: Jun. 2012 )		(A: Jun. 2011 )		(A: Jun. 2012 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets )	/ count )
		(A: Jun. 2012 )		(A: Jun. 2011 )		(A: Jun. 2012 )
	=	-9.952	/	( (-22.119	+	7.033 )	/ 2 )
	=	-9.952	/	-7.543
	=	N/A %

Audeo Oncology's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2012 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(Q: Sep. 2012 )		(Q: Jun. 2012 )		(Q: Sep. 2012 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets)	/ count )
		(Q: Sep. 2012 )		(Q: Jun. 2012 )		(Q: Sep. 2012 )
	=	-20.54	/	( (7.033	+	2.061)	/ 2 )
	=	-20.54	/	4.547
	=	-451.73 %

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2012) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

Audeo Oncology (DELISTED:AURX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Audeo Oncology Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Return-on-Tangible-Equity

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.